Medical/Pharmaceuticals
Unveiling a Smarter Future for Dentistry at China Dental Show 2026
AI-powered clinical solutions, hands-on experiences and global business opportunities will come together in Shanghai from October 13 to 16 SHANGHAI, Aug. 10, 2026 /PRNewswire/ -- China Dental Show 2026 (CDS 2026) will take place from October 13 to 16 at the National Exhibition and Convention Cen...
2026-08-10 21:00
2932
NYSE Content Update: Goldman Sachs Asset Management Launches Two New ETFs
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Aug. 10, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begin...
2026-08-10 20:56
5722
POMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth Engine
GUANGZHOU, China, Aug. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its healthcare intelligence flywheel, a clos...
2026-08-10 20:00
3399
Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
-ASC36_35FDC, a once-monthly subcutaneous (SQ) fixed dose combination (FDC) injection of ASC36 and ASC35, is a potentially first-in-class drug candidate which targets three validated targets of amylin receptor, GLP-1R and GIPR. -ASC36 is a potentially first-in-class once-monthly to once-quarterly...
2026-08-10 19:00
3939
Dx&Vx Signs Two Material Transfer Agreements in Latin America Within Two Months -- "Technology Validated Across Both Public and Private Sectors"
— Argentine biopharmaceutical company in July, South American public health institution in August sign consecutive KRNA material transfer agreements — Two of five cumulative MTAs now in Latin America, as company accelerates entry into the region's pharmaceutical market SEOUL, South Korea, Aug. 10...
2026-08-10 17:36
2777
/C O R R E C T I O N -- United Imaging/
In the news release, Chinese and Indonesian cardiologists complete Southeast Asia's first "noise-free" cardiac procedure in Jakarta, issued 09-Aug-2026 by United Imaging over PR Newswire, the 2nd paragraph, 1st sentence, should read "The procedure, performed recently" rather than "The procedure, ...
2026-08-10 16:45
4317
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (bsADC), i...
2026-08-10 12:05
2119
2026 Global Health Summit Opens in Hong Kong -- Global Healthcare Leaders Convene: Bringing Breakthroughs to Patients
HONG KONG, Aug. 10, 2026 /PRNewswire/ -- The 2026 Global Health Summit ("GHS 2026"), jointly hosted by New Frontier Group ("New Frontier") and the Hong Kong Investment Corporation Limited ("HKIC"), opened today at the Hong Kong Convention and Exhibition Centre for a two-day programme. Held under ...
2026-08-10 11:00
739
Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections
SHANGHAI, Aug. 9, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces that its wholly-owned subsidiary T-mab has successfully passed Brazilian Health Regulatory Agency's ("ANVISA") GMP on-site inspect...
2026-08-10 08:00
2218
RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX e...
2026-08-08 15:46
4225
Alebund's AP301 NDA Accepted for Review by China's NMPA
SHANGHAI, Aug. 7, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the New Drug Application (NDA) for AP301 capsules, a novel oral iron-based phosphate binder, for the treatmen...
2026-08-07 18:40
2822
Check out Hainan's Pioneering Medical Hub
Uncover the New Charms of Boao Lecheng Medical Tourism HAIKOU, China, Aug. 7, 2026 /PRNewswire/ -- A news report from PDDC: Coastal scenery soothes body and mind, while cutting‑edge medical services empower health‑and‑wellness tourism. Bolstered by the opening‑up dividends of Hainan Free Trade P...
2026-08-07 18:27
2746
Yochanra®, the World's First Innovative Drug to Overcome FGFR Inhibitor Resistance, Makes Its Global Debut in China
NANJING, China and GAITHERSBURG, Md., Aug. 7, 2026 /PRNewswire/ -- TransThera Sciences' Yochanra® is the first drug independently developed in China to address the longstanding global challenge of acquired resistance to FGFR inhibitor therapy in patients with cholangiocarcinoma. On 6 August 2026,...
2026-08-07 14:44
3609
CLASSYS Appoints Former Samsung Electronics and Vuno Executive Dr. Taek-Soo Kim as Chief Technology Officer, Accelerating Its Evolution into a Global Medical Aesthetics Technology Company
SEOUL, South Korea, Aug. 7, 2026 /PRNewswire/ -- CLASSYS (KOSDAQ: 214150), a global medical aesthetics platform company, announced the appointment of Dr. Taek-Soo Kim, a distinguished technology management expert, as its new Chief Technology Officer (CTO) and Head of Research and Development. ...
2026-08-07 08:16
4690
Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS
NANTONG, China, Aug. 6, 2026 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics, today announced the completion of patient enrollment and initial dosing across all cohorts in its Phase II clinical trial evaluating RAG-17, an ...
2026-08-06 19:30
1878
Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq
SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq on August 5, 2026 Beijing time. Attovia Therapeutics (Nasdaq: ATTO) issued shares at a price of $17.00 per sha...
2026-08-06 18:46
3414
Harbour BioMed Appoints Dr. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment ...
2026-08-06 16:10
2617
Chugai Pharma Taiwan (CPT) Secures Dual Recognition at the Asia Responsible Enterprise Awards (AREA) for Health Promotion and Green Leadership Initiatives
SINGAPORE, Aug. 6, 2026 /PRNewswire/ -- Chugai Pharma Taiwan (CPT) was recognized at the Asia Responsible Enterprise Awards (AREA) 2026organised by Enterprise Asia under the Health Promotion and Green Leadership categories for its integrated ESG approach that advances human health, employee well-...
2026-08-06 15:11
2954
Fosun International Wins Three Awards from Global Banking & Finance Review, Gaining International Recognition for its ESG Performance, Corporate Social Responsibility, and Brand Strength
HONG KONG, Aug. 6, 2026 /PRNewswire/ -- Recently, Global Banking and Finance Review, a leading British financial magazine, announced its 2026 award winners. Fosun International Limited (HKEX stock code: 00656) received three awards in recognition of its outstanding contributions to sustainable de...
2026-08-06 13:17
5304
From Patient to Storyteller: Dale Returns to Shanghai After CAR-T Recovery, Sharing a Journey of Hope
SHANGHAI, Aug. 5, 2026 /PRNewswire/ -- After overcoming stage 4B lymphoma through CAR-T therapy, New Zealand patient Dale has returned to Shanghai—not as a patient seeking treatment, but as a survivor sharing his story. Recently, Dale came back to the city where he received life-changing care, to...
2026-08-06 08:57
1940
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 315 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 313 media titles]
2026-08-27 10:25
AIMX Singapore 2026 Accelerates AI Deployment Through Catalysing Industry Innovation and Advancing Global Collaborations
[Picked up by 304 media titles]
2026-08-24 10:00
Henox and Nexusguard Announce Strategic Alliance at BATIC 2026 to Power and Protect the Next Generation of Digital Infrastructure
[Picked up by 297 media titles]
2026-08-25 10:00OGA 2026 Positions Kuala Lumpur as the Regional Marketplace for Southeast Asia's Energy Growth
[Picked up by 291 media titles]
2026-08-24 15:42
Most Read
AIMX Singapore 2026 Accelerates AI Deployment Through Catalysing Industry Innovation and Advancing Global Collaborations
2026-08-24 10:00
15058
OGA 2026 Positions Kuala Lumpur as the Regional Marketplace for Southeast Asia's Energy Growth
2026-08-24 15:42
14852
Rewarding Meetings Begin At Hyatt Regency Kuala Lumpur At KL Midtown
2026-08-25 07:00
12888
Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
2026-08-27 10:25
8460